Core Scientific, Inc. (CORZ) Financial Statements
Core Scientific, Inc. (CORZ) reported trailing twelve-month revenue of $440.3M (up 26.4% year on year) and net income of -$1.4B as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$1.2B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CORZCore Scientific, Inc.Follow CORZ — free
—
Price chart with a free account
- Market cap
- 4.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Revenue | 0.64 | 0.50 | 0.51 | 0.32 | 0.44 | |
| Gross profit | 0.01 | 0.12 | 0.12 | 0.04 | 0.12 | |
| Research & development | 0.03 | 0.01 | 0.01 | — | — | |
| Operating income | -2.11 | 0.01 | -0.14 | -0.25 | -0.56 | |
| Pre-tax income | -2.16 | -0.25 | -1.44 | -0.29 | -1.43 | |
| Income tax | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net income | -2.15 | -0.25 | -1.44 | -0.29 | -1.43 | |
| Diluted EPS ($) | -6.30 | -0.65 | -4.87 | -0.88 | -4.23 | |
| Diluted shares (bn) | 0.341 | 0.380 | 0.256 | 0.318 | — |
USD billions · SEC XBRL
Core Scientific, Inc. — questions
- What is Core Scientific, Inc.'s revenue?
- $440.3M over the twelve months to 2026-06-30, up 26.4% year on year, from its 10-Q and 10-K filings.
- What is Core Scientific, Inc.'s net income?
- -$1.4B over the twelve months to 2026-06-30.
- What is Core Scientific, Inc.'s free cash flow?
- -$1.2B over the twelve months to 2026-06-30.
- What are Core Scientific, Inc.'s diluted earnings per share?
- $-4.23 over the twelve months to 2026-06-30.
Every figure on this page comes from Core Scientific, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.